Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$130 Mln
P/E Ratio
--
P/B Ratio
0.34
Industry P/E
--
Debt to Equity
0.13
ROE
-0.66 %
ROCE
-59.55 %
Div. Yield
0 %
Book Value
1.47
EPS
-1.31
CFO
$-580.90 Mln
EBITDA
$-852.11 Mln
Net Profit
$-844.68 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lyell Immunopharma Inc (LYEL)
| -32.25 | -25.93 | -22.42 | -82.01 | -56.83 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Lyell Immunopharma Inc (LYEL)
| -66.71 | -44.09 | -55.17 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches,... such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080 Read more
Founder & Executive Chairman
Dr. Richard D. Klausner M.D.
Founder & Executive Chairman
Dr. Richard D. Klausner M.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lyell Immunopharma Inc (LYEL) stood at $ 491 Mln as on 31-Dec-24
The share price of Lyell Immunopharma Inc (LYEL) is $0.43 (NASDAQ) as of 17-Apr-2025 16:02 EDT. Lyell Immunopharma Inc (LYEL) has given a return of -56.83% in the last 3 years.
Lyell Immunopharma Inc (LYEL) has a market capitalisation of $ 130 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lyell Immunopharma Inc (LYEL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lyell Immunopharma Inc (LYEL) and enter the required number of quantities and click on buy to purchase the shares of Lyell Immunopharma Inc (LYEL).
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Richard D. Klausner M.D.. is Lyell Immunopharma Inc (LYEL), and CFO & Sr. VP is Dr. Richard D. Klausner M.D..
There is no promoter pledging in Lyell Immunopharma Inc (LYEL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Lyell Immunopharma Inc (LYEL) | Ratios |
|---|---|
|
Return on equity(%)
|
-66.1
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-562285.25
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lyell Immunopharma Inc (LYEL) was $0 Mln.
$-0.01
(
